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Abstract (250 words) 
Salmeterol is a long acting beta2-agonist (LABA) widely used for treatment of airways disease. 
There is evidence that beta2-agonists, including salmeterol, have the potential for performance 
enhancing effects when delivered at supratherapeutic doses. For this reason, all beta2-agonists 
are currently on the Prohibited List issued by the World Anti-Doping Agency (WADA) 
regardless of dosing route with some exemptions for inhaled salbutamol, formoterol, and 
salmeterol when used at therapeutic inhaled doses. For 2020, salmeterol use is permitted up to 
a therapeutic dosing threshold of 200 µg daily, but unlike salbutamol and formoterol, there is 
an anomaly; currently there is no urine threshold to control for supratherapeutic dosing beyond 
this dosing threshold. Salmeterol, however, is reportable as an Adverse Analytical Finding 
(AAF) at levels above 10 ng/ml. Complicating matters is that following inhalation, salmeterol 
parent drug is present at relatively low levels compared to other beta2-agonists due to rapid 
metabolism to the metabolite, alpha-hydroxysalmeterol, which is typically present at higher 
levels than parent drug. Moreover, peak parent drug levels following permitted therapeutic 
dosing are below the minimum required performance level (MRPL) of 10 ng/ml for salmeterol 
(50% of the MRPL that analytical laboratories are required to meet for non-threshold beta2-
agonists), hence the presence of salmeterol may be unreported. For consistency, a urine 
threshold should be introduced for salmeterol as matter of priority, to balance the needs of 
athletes that use salmeterol therapeutically up to the agreed dosing threshold, with the need to 









Salmeterol is a long acting beta2-agonist (LABA) that is widely used for the treatment of 
airway disease, particularly asthma. Salmeterol is usually delivered via metered dose inhaler 
(MDI) or dry powder inhaler (DPI) twice daily and is used as a “symptom controller” with a 
duration of action around 12 hours compared to the short-acting beta2-agonist (SABA) 
salbutamol with a duration of action around 4 hours. Salmeterol is also a chiral compound and 
is usually administered as the racemate (50:50 mixture of (R)- and (S)-salmeterol), with (R)-
salmeterol being the active enantiomer 1. Enantiopure (R)-salmeterol is reportedly available for 
purchase online via chemical supply vendors. 
 
There is solid evidence that members of the beta2-agonist drug class, including salmeterol, 
have the potential for performance enhancing effects when delivered at supratherapeutic doses. 
When administered at acute high doses, beta2-agonists can enhance muscle power and sprint 
performance 2-8, and if taken for longer periods, they possesses muscle anabolic properties 9-11, 
as recently reviewed12. For this reason, all beta2-agonists are on the 2020 Prohibited List issued 
by the World Anti-Doping Agency (WADA) 13 regardless of dosing route – albeit with three 
exemptions. Salbutamol, formoterol, and salmeterol are allowed by inhalation at therapeutic 
doses up to a dosing threshold. The therapeutic dosing threshold for salmeterol is 200 µg daily. 
However, unlike salbutamol and formoterol, there is no urine threshold for salmeterol. Despite 
being reportable at levels above 10 ng/ml (50% of the Minimum Required Performance Level 
(MRPL) 14, an unscrupulous athlete could inhale salmeterol at high doses with relative 
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Here we outline the potential for supratherapeutic misuse of salmeterol and argue that a urine 
threshold needs to be introduced as a matter of priority. 
 
2. Salmeterol as a performance enhancing drug 
Few studies have investigated the potential performance-enhancing effects of salmeterol in 
humans. Early work in athletes suggested that used acutely at therapeutic low doses (50 µg), 
salmeterol did not enhance running performance, cycling anaerobic power or muscle strength 
15,16. However, more recent work has demonstrated that daily inhaled treatment with salmeterol 
(100 µg twice daily) enhanced 30 m sprint performance during a period of 5 weeks in 
combination with a power and strength program 17. To our best knowledge, no study has been 
performed in humans that had muscle hypertrophy as an outcome measure, but studies in 
rodents show that salmeterol possesses anabolic properties. Thus, there appears to be beneficial 
effects in rat muscle 18 as well as rat dosing studies 19. The work by Moore et al 19 was based 
on the theory that a long duration of action is required for beta2-agonists to evoke an anabolic 
response, and compared the potent anabolic relatively non-selective beta2-agonist clenbuterol 
with salmeterol by equimolar dosing of rats via different routes of administration. Given orally, 
salmeterol caused significant increases in body and carcass weight, and in the mass of mixed 
fibre gastrocnemius/plantaris and tibialis anterior muscles, but no increase in slow-twitch 
soleus muscles 19. These effects were similar to that observed with clenbuterol, apart from an 
additional response seen in soleus muscle. However, when given by infusion, salmeterol 
demonstrated a dramatic increase in soleus muscle mass. These results indicate that the 
anabolic potency of salmeterol in vivo is dependent on the route of administration; this is highly 
relevant to dosing via the inhaled route where first-pass metabolism is limited to the swallowed 
fraction. The other findings from this work were that slow-twitch muscles are less sensitive 
than mixed-fibre muscles, and observance of ergogenic effects in humans may be 
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muscle/exercise test specific, possibly accounting for some of the negative findings in older 
athlete studies. Ryall et al 20 examined the effect of intra-peritoneal injections of formoterol 
and salmeterol in rats for therapeutic applications in muscle wasting disease. It was found that 
while formoterol was more potent than salmeterol, salmeterol demonstrated greater muscle 
hypertrophy (~12%) in the extensor digitorum longus (fast twitch) and soleus (slow twitch) 
muscle compared to formoterol, and that both drugs used at around 25 microgram/kg/day are 
capable of eliciting skeletal muscle hypertrophy with minimal effects on heart muscle. A 
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3. Salmeterol on the Prohibited List 
Salmeterol, like formoterol and salbutamol, is permitted to be used via inhalation under certain 
dosing thresholds to allow athletes with asthma to compete. These thresholds are designed to 
distinguish between therapeutic dosing (need to treat asthma symptoms) and supratherapeutic 
dosing (where a performance benefit may be obtained).  
Thresholds for salbutamol and formoterol consist of dosing via the inhalation route (metered 
dose inhaler) with a maximum permitted dose in a 12 and 24 hour period, respectively 13, 
importantly with corresponding urine thresholds 22 to limit the potential for supratherapeutic 
dosing for doping purposes. For salmeterol, there is only a dosing threshold with no 
corresponding urine threshold. Despite the drug being detectable in urine, this effectively 
means there is no practical way to limit supratherapeutic dosing other than relying on an 
athlete’s honesty to report their dose in the previous 24 hours. This is a similar situation to the 
SABA terbutaline when administered under a Therapeutic Use Exemption (TUE) 23. 
A review of anti-doping figures for the three permitted beta2-agonists, salbutamol, formoterol, 
and salmeterol, from publicly available sources indicate that there are only a relatively small 
number of Adverse Analytical Findings (AAFs) attributable to salmeterol as shown in Table 2. 
Salmeterol, present as the un-metabolised parent drug, is reportable as an AAF at levels above 
10 ng/ml (50% of the Minimum Required Performance Level (MRPL)) 14. From 2010, there 
has been a significant change in formoterol AAFs per year, a result of formoterol being 
permitted to be used with corresponding dosing and urine threshold from 2012 onwards. While 
there appears to be low numbers of salmeterol AAFs, this is most likely due to differences in 
the pharmacokinetics of salmeterol compared to salbutamol and formoterol, which results in 
very low urine concentrations as discussed below. 
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4. Urine levels following dosing 
Only a few studies have reported urinary levels of salmeterol or the alpha-hydroxy metabolite, 
with reports in horses 25,26 and humans 27-29. Data on salmeterol urinary levels from human 
studies are summarised in Table 3.  
Part of the reason for the lack of data is the relatively low concentrations observed in urine 
meaning the assay is technically demanding, particularly for routine screening. As reported by 
Hostrup et al 27, the median urine concentration of the alpha-hydroxysalmeterol metabolite after 
4 hours was 2.9 ng/ml, and the median salmeterol concentration was around 8-fold lower at 
0.38 ng/ml in non-athletes male subjects who inhaled a 100 microgram dose via a DPI device 
in resting conditions.  
A survey of 7045 routine doping urine samples collected over 1 year, demonstrated that only 
a small number (0.6%, 45/7045 samples) contained salmeterol, and only eight had levels 
higher than 0.5 ng/ml, with the two highest at 1.81 ng/ml and 1.29 ng/ml 28. This was similar 
to the maximum observed concentration in an accompanying excretion volunteer study (1.27 
ng/ml) 28. The most remarkable result was that only 8 samples had a concentration higher 
than 0.5 ng/ml, meaning that 87% of the samples had a concentration below the lower limit of 
quantification of the method. Interestingly from the same manuscript in a volunteer study; in 
6 subjects who inhaled an acute dose of 100 microgram salmeterol (MDI device), nine 
samples (50%, 9/18 samples) were above 0.5 ng/ml compared to 18% (8/45) in the doping 
control figures where salmeterol was detected. This difference should be largely attributed to 
sampling outside the time of peak excretion, highlighting that doping control figures cannot 
be meaningfully compared with clinical pharmacokinetics studies. 
In terms of published clinical studies, there are only two other studies 27,30. Our salmeterol 
study 30 demonstrated a median (range) of 0.08(3) ng/ml for a 50 µg dose, and 2.1(5) ng/ml for 
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a 200 µg dose both with urine at 2 h. Both of these doses have not been previously reported so 
any direct comparison is challenging. Studies at a 100 µg dose have been reported 27,28 but 
unlike salbutamol, there is no information on the linearity of the dose-urine concentration 
relationship 31 so concentrations cannot be extrapolated either up or down. Based on a 
comparison of the three different dosages now reported (50, 100, 200 µg), it appears that this 
relationship may not be linear at least for peak levels (Figure 1) and appears also highly variable 
– this is a different situation to salbutamol which is metabolised via a different pathway and is 
linear 31. Observation of our previous data 30 shows that at the 50 µg dose, one subject had 
noticeably high levels compared to the other subjects, but the remainder were less than 0.16 
ng/ml which is less than half the median observed by Hostrup et al 27 and less than a quarter of 
that for Deventer et al 28 . At the 200 µg dose, there was another  high outlier (5.7 ng/ml), but 
the remainder of samples were below 3.5 ng/ml, with a median of 2.1 which was higher than 
both the Hostrup et al 27 (median 0.38) and Deventer et al 28 (median of 0.64 ng/ml) studies. 
Both the Hostrup et al 27 and Deventer et al 28 studies were half the dose. In addition, the 
Hostrup et al 27 samples were corrected for SG whereas salmeterol samples from our study 30  
were not corrected for SG. In-house data from our laboratory reveal an inter-subject variability 
upwards of 50% for urine salmeterol levels, whereas the intra-subject variability is around 40% 
for urine levels, but only 20% for 0-12-h excretion.  
 
Given the extensive CYP3A4 metabolism of salmeterol, the large inter-subject variability may 
also be explained by inter-subject pharmacogenetic differences for this enzyme 32, as well as 
significant potential for dietary inhibitors (well known CYP3A4 dietary inhibitors such as 
grapefruit juice etc.), which was not controlled in any of these urine levels studies. Like the 
other beta2-agonists, salbutamol and terbutaline, exercise and dehydration are likely to have a 
significant effect on urine levels and increase the chance of exceeding any threshold limits 33,34. 
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To account for this, the urine decision limits for threshold substances, such as salbutamol and 
formoterol, are adjusted to a USG of 1.020 if the urine samples exceed a USG of 1.018 + 0.002 
(the latter represent the maximum uncertainty for the USG measurement). Hence, if a threshold 
is to be introduced for salmeterol, the corresponding decision limit would be adjusted upwards 
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5. The salmeterol anomaly 
Based on the observations that salmeterol possesses muscle anabolic effects in rodents, and 
that other beta2-agonists within the same drug class can enhance muscle power and sprint 
performance, abductive reasoning suggests that salmeterol’s place on WADAs 2020 Prohibited 
List is warranted. Unlike salbutamol and formoterol that are permitted to be used below a 
dosing threshold, along with a corresponding urine threshold to limit supratherapeutic dosing, 
salmeterol only has a dosing threshold with no published urine threshold.  
The minimum required performance level (MRPL), is the minimum concentration of a 
prohibited substance, metabolite or marker that can be reliably detected and identified in 
routine daily operations, and is used for non-threshold substances.14  The basic premise of the 
MRPL is that it harmonises the analytical methods of performance for non-threshold 
substances across the world. The MRPL for the S3 beta2-agonist class is 20 ng/ml,  and 
salmeterol is reportable as an AAF at levels above 10 ng/ml (50% of the Minimum Required 
Performance Level (MRPL).14 This level is around 5-10-fold higher than maximum levels 
typically observed following salmeterol inhalation therapy. The fact that salmeterol has a 
dosing threshold but no urine threshold 22 appears an anomaly in itself, aside from the fact that 
even if salmeterol has a reporting limit (50% MRPL), unlike salbutamol and formoterol, 
laboratories may not necessarily be capable of measuring salmeterol down to the required level 
where the active drug is likely to be found (Table 3). Similarly, while the active metabolite 
appears to be a suitable candidate to measure salmeterol via inhalation and thus act as a urine 
threshold analyte 27, there is no provision to measure the alpha-hydroxysalmeterol metabolite, 
either as a threshold or non-threshold substance, and for this to be reported as an AAF.  
To our knowledge there is no published research linking the seemingly arbitrary urine 
concentration of 10 ng/ml (50% MRPL) to the maximum dose threshold of 200 μg. Moreover, 
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this 10 ng/ml  level could be considered generous when considering peak levels from a maximal 
dose (200 μg) from two studies have been 5.7 ng/ml (Table 3). This could potentially lead to a 
situation where an athlete could essentially use as much inhaled salmeterol as they wish, limited 
only by adverse effects. If an AAF did arise, it could be claimed that the result was attributable 
to maximum threshold dosing levels. The administration route could also be parenteral or oral 
if so desired. With no way of checking for dosing compliance using a urine threshold, 
supratherapeutic use could result in performance enhancements and athlete harm. 
 
Conclusion 
Salmeterol is likely to be performance enhancing in supratherapeutic doses and is allowed in- 
and out of competition but since there is no urine threshold, there is currently no way of 
ensuring use is restricted to dosing thresholds apart from the seemingly arbitrary requirement 
for reporting at 10 ng/ml. Despite some limitations, the urine thresholds introduced by WADA 
for salbutamol and formoterol to restrict supratherapeutic dosing works well for the vast 
majority of athletes who use beta2-agonists therapeutically under permitted regimens. For 
consistency, a urine threshold should also be introduced for salmeterol as matter of priority, to 
balance the needs of athletes that use salmeterol therapeutically up to the agreed dosing 
threshold, with the need to control supratherapeutic dosing for doping purposes and athlete 
harm minimisation. Further work would be required to ascertain whether the metabolite or 
parent drug would be the best candidate, and the apparent non-linear dose-urine concentration 
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Table 1. In vivo studies of salmeterol effects on muscle mass. 
 
Study Dose Species Duration Effect 
Tibialis anterior 
(increased mass, mg 




(increased mass, mg 
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Table 3. Data on urine concentrations of salmeterol after inhaled administration in humans 
    Individuals’ peak salmeterol 





Study Type Dose Subjects max mean median max mean median   





Healthy (23-39 yrs), n=6 1.3 0.6 0.6 - - - 2 h post dose 
          
Biobank analysis of 45 
anonymized samples 
containing salmeterol 
Unknown Athletes 1.8 - - - - - n/a 
                    





Asthmatics, n=10 0.6 0.3 0.4 7.6 3.9 3.8 0-4 h post dose 
Non-asthmatics, n=10 0.7 0.4 0.4 12.3 4.1 3.7 0-4 h post dose 





Healthy, n=6 3 0.6 0.1 - - - 2 h post dose 
200 µg 
(DPI) 
Healthy, n=4 5.7 2.6 2.1 - - - 2 h post dose 
                  





Healthy, n=7 0.9 0.4 0.3 15.1 4.6 3.1 0-8 h post dose 
200 µg 
(DPI) 
Athletes, n=14 5.7 2.5 2.0 30.9 6.0 3.3 0-6 h post dose 
DPI: dry-powder inhalation; MDI: metered dose inhaler; PK: pharmacokinetics. *analysis by WADA accredited laboratory 
 
 




Figure 1.  Comparison of median (panel A) and maximum (panel B) free salmeterol urine 
concentrations from studies reported in Table 3 demonstrating a linear dose-urine relationship for 
median levels and a non-linear dose-urine relationship for peak concentrations. 
 
